Determination of IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies-Reference-Cited by-同舟云学术

Determination of IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies

Published:2019-06-27 Issue:5 Volume:21 Page:
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Zhang Ting-Ting,Ma Junli,Durbin Kenneth R.,Montavon Timothy,Lacy Susan E.,Jenkins Gary J.,Doktor Stella,Kalvass J. Cory

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

http://link.springer.com/content/pdf/10.1208/s12248-019-0352-8.pdf

Reference72 articles.

1. Szollosi DE, et al. Current and novel anti-inflammatory drug targets for inhibition of cytokines and leucocyte recruitment in rheumatic diseases. J Pharm Pharmacol. 2017.

2. Mizuma A, Yenari MA. Anti-inflammatory targets for the treatment of reperfusion injury in stroke. Front Neurol. 2017;8:467.

3. Krebs CF, Schmidt T, Riedel JH, Panzer U. T helper type 17 cells in immune-mediated glomerular disease. Nat Rev Nephrol. 2017;13(10):647–59.

4. Yago T, et al. IL-23 and Th17 disease in inflammatory arthritis. J Clin Med. 2017;6:9.

5. Sadeghi M, et al. IL-23 plasma level is strongly associated with CMV status and reactivation of CMV in renal transplant recipients. BMC Immunol. 2016;17(1):35.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease;Gastroenterology;2024-06

2. HPLC-Parallel accelerator and molecular mass spectrometry analysis of 14C-labeled amino acids;Journal of Chromatography B;2023-02

3. Utility of in silico prediction of target suppression for antibodies against soluble targets: static versus dynamic models;European Journal of Clinical Pharmacology;2022-11-22

4. Pipeline Impact of Radiolabeled Compounds in Drug Discovery and Development;ACS Medicinal Chemistry Letters;2022-09-16

5. Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model;Pharmaceutics;2021-09-30